1036931-36-8

Basic information

• Product Name: (2S,3R)-3-amino-4-cyclobutyl-2-hydroxybutanamide hydrochloride
• Synonyms: (2S,3R)-3-amino-4-cyclobutyl-2-hydroxybutanamide hydrochloride;(alphaS,betaR)-beta-Amino-alpha-hydroxycyclobutanebutanamide hydrochloride (1:1)
• CAS NO: 1036931-36-8
• Molecular Formula: C8H16N2O2.HCl
• Molecular Weight: 208.68578
• Mol File: 1036931-36-8.mol
• Article Data: 25

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2S,3R)-3-amino-4-cyclobutyl-2-hydroxybutanamide hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3R)-3-amino-4-cyclobutyl-2-hydroxybutanamide hydrochloride(1036931-36-8)
• EPA Substance Registry System: (2S,3R)-3-amino-4-cyclobutyl-2-hydroxybutanamide hydrochloride(1036931-36-8)

Safety Data

• Hazardous Substances Data: 1036931-36-8(Hazardous Substances Data)

Usage

General Description

"(2S,3R)-3-amino-4-cyclobutyl-2-hydroxybutanamide hydrochloride" is a chemical compound that is a hydrochloride salt form of (2S,3R)-3-amino-4-cyclobutyl-2-hydroxybutanamide. It is a compound with potential pharmaceutical applications and may be used in research and development. The chemical structure includes a cyclobutyl ring and an amino group, which could potentially contribute to its pharmacological properties. The hydrochloride salt form enhances the solubility and stability of the compound, making it more suitable for pharmaceutical applications. Overall, "(2S,3R)-3-amino-4-cyclobutyl-2-hydroxybutanamide hydrochloride" is a compound with potential medicinal uses and may be of interest to researchers and pharmaceutical companies.

Upstream product

• 1036931-37-9 3-amino-4-cyclobutyl-2-hydroxybutanoic acid 
• 1416790-87-8 5-[1-[(tert-butylsulfinyl)amino]-2-cyclobutylethyl]-2-phenyl-1,3-oxazol-4-yl trifluoromethanesulfonate 
• 1416790-86-7 C₁₀H₁₉NOS 
• 885280-12-6 ethyl 4-cyclobutyl-3-oxobutanoate 
• 4415-82-1 cyclobutanemethanol 
• 63659-30-3 cyclobutylmethyl methanesulfonate 
• 4426-03-3 cyclobutyl acetonitrile 
• 1433545-85-7 3-[(tert-butoxycarbonyl)amino]-4-cyclobutyl-1-ethoxy-1-oxobut-2-yl 4-methoxybenzoate 
• 1433545-74-4 (2E)-3-amino-4-cyclobutyl-1-ethoxy-1-oxobut-2-en-2-yl 4-methoxybenzoate 
• 1433545-62-0 4-cyclobutyl-1-ethoxy-1,3-dioxobutan-2-yl 4-methoxybenzoate 
• 1433545-53-9 ethyl 2-chloro-4-cyclobutyl-3-oxobutanoate 
• 17247-58-4 (Bromomethyl)cyclobutane 
• 1025799-39-6 2-(benzhydrylidene-amino)-3-cyclobutyl-propionic acid ethyl ester 
• 394735-17-2 ethyl 2-amino-3-cyclobutylpropanoate 

Downstream Products

• 394735-28-5 (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicylo[3.1.0]-hexane-2-carboxamide 
• 394735-28-5 C₂₇H₄₇N₅O₅ 
• 394735-28-5 C₂₇H₄₇N₅O₅ 
• 1428533-54-3 3-(2-(6-benzyl-3-(3-(tert-butyl)ureido)-5-chloro-2-oxopyrazin-1(2H)-yl)acetamido)-4-cyclobutyl-2-oxobutanamide 

Relevant articles and documents

N - benzyl -4 - cyclobutyl -2 - hydroxy -3 - nitryl Ding amide and use thereof

The invention relates to a new compound, and in particular relates to N-benzyl-4-cyclobutyl-2-hydroxy-3-nitrobutyrylamide and use thereof, and belongs to the technical field of the preparation of medicine and other fine chemical products. The structural formula of the N-benzyl-4-cyclobutyl-2-hydroxy-3-nitrobutyrylamide is shown in the specification; the compound is used for synthesizing beta-amino-alpha-hydroxy cyclobutane butyrylamide hydrochloride (formula I). According to the preparation method of N-benzyl-4-cyclobutyl-2-hydroxy-3-nitrobutyrylamide, the raw materials 2-nitroethyl cyclobutane (formula III) and N-benzyl-2-oxoacetamide (formula IV) are condensed in an alkaline environment in the presence of an organic solvent to obtain N-benzyl-4-cyclobutyl-2-hydroxy-3-nitrobutyrylamide.

A intermediate pope Switzerland Wei 2-hydroxy-3-amino-4-cyclobutyl butanamide hydrochloride synthetic method

The invention relates to a synthetic method of a boceprevir intermediate namely 2-hydroxy-3-amino-4-cyclobutane amide hydrochloride, belonging to the technical field of medicament synthesis. By adopting the synthetic method, the problems that a method for synthesizing the boceprevir intermediate is high in cost, complex in reaction, low in efficiency and the like in the prior art can be solved. The synthetic method comprises the following steps: by adopting cyclobutyl acetate and monomethyl mono potassium malonate as raw materials, reacting for 10-12 hours at room temperature under the action of an activating agent and magnesium chloride; sequentially adding an oxidizing agent, 4-cyclobutyl-3-oxo-ethyl butyrate and a catalyst into methanoic acid at 15-20 DEG C, and reacting for 1.5-2.5 hours at 15-20 DEG C; adding a condensation agent and organic alkali at 10-15 DEG C, performing condensation reaction with ammonium chloride at room temperature, and reacting for 10-12 hours; and finally performing ammoniation and acidification to obtain a final product. The synthetic method disclosed by the invention is relatively low in cost, simple in reaction condition, less in reaction step and short in time, and the final product, namely the boceprevir intermediate, is relatively high in purity and yield.

Achiral pyrazinone-based inhibitors of the hepatitis C virus NS3 protease and drug-resistant variants with elongated substituents directed toward the S2 pocket

Herein we describe the design, synthesis, inhibitory potency, and pharmacokinetic properties of a novel class of achiral peptidomimetic HCV NS3 protease inhibitors. The compounds are based on a dipeptidomimetic pyrazinone glycine P3P2 building block in combination with an aromatic acyl sulfonamide in the P1P1′ position. Structure-activity relationship data and molecular modeling support occupancy of the S2 pocket from elongated R6 substituents on the 2(1H)-pyrazinone core and several inhibitors with improved inhibitory potency down to Ki = 0.11 μM were identified. A major goal with the design was to produce inhibitors structurally dissimilar to the di- and tripeptide-based HCV protease inhibitors in advanced stages of development for which cross-resistance might be an issue. Therefore, the retained and improved inhibitory potency against the drug-resistant variants A156T, D168V, and R155K further strengthen the potential of this class of inhibitors. A number of the inhibitors were tested in in vitro preclinical profiling assays to evaluate their apparent pharmacokinetic properties. The various R6 substituents were found to have a major influence on solubility, metabolic stability, and cell permeability.